This volume contains the highlights of an American College of Neuropsychopharmacology conference on new directions in the development of a typical and other novel antipsychotic drugs. An international group of psychiatrists from leading medical centres and researchers from universities and the pharmaceutical industry presents new theories and preclinical and clinical data on various drugs and classes of drugs, including amperozide and other clozapine-type drugs, substituted benzamides, dopamine partial agonists, dopamine autoreceptor agonists. D1, D3 and D4 antagonists, milacemide, glycine, sigma antagonists, and 5-HT3 antagonists. The contributors develop concepts on the receptor selectivities and mechanisms of action of a typical neuroleptics and identify various receptors and neurochemical mechanisms as new targets for antipsychotic drugs. The book includes a clinical overview of risperidone and discussions on the pattern of efficacy of clozapine in treatment resistant schizophrenia, the mechanism of action of clozapine in relation to its clinical advantages, and the efficacy and tolerability of novel dopamine agonists.